A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B.
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- 20 Mar 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 09 May 2011 Planned End Date changed from 1 Apr 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date (1 Apr 2010) added as reported by ClinicalTrials.gov.